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Obesity and Lymphovascular Invasion in Women
with Uterine Endometrioid Carcinoma
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ADNAN MUNKARAH4 and MOHAMED A. ELSHAIKH1

Department of 1Radiation Oncology, 2Public Health Science, 3Pathology and 4Division of Gynecologic Oncology,
Department of Women’s Health Services, Henry Ford Hospital, Detroit, MI, U.S.A.

Abstract. Aim: Obesity is classically linked to type I
endometrial cancer (EC). Lymphovascular invasion (LVI) is
a well-known adverse prognostic factor in EC. In other
disease sites, it has been reported that obesity and LVI are
strongly associated. The objective of the present study was to
investigate the association between obesity and LVI in women
with EC. Patients and Methods: For this Institutional Review
Board (IRB)-approved study, we reviewed our prospectivelymaintained uterine cancer database of 1,950 patients with EC
International Federation of Gynecology and Obstetrics
(FIGO) stages I-IV who underwent hysterectomy from 1/1988
through 12/2011. Bivariate and multivariate analyses were
conducted to investigate the relationships between obesity, as
measured by body mass index (BMI) at the time of
hysterectomy and tumor features including LVI. Results: A
total of 1,341 patients with uterine endometrioid carcinoma
were identified. All patients underwent hysterectomy, and
salpingoophrectomy with or without lymph node dissection.
The median BMI for study patients was 34.3 (range=15.771.3) kg/m2. 46.8% of the patients were morbidly obese. 625
patients (46.7%) were <60 years at diagnosis with a median
BMI of 36.31 (range=19.7-69.8) kg/m2 while the median BMI
for women 61 years or older was 32.2 (15.7-71.3) kg/m2
(p=0.002). In univariate analyses, high BMI was not
significantly associated with LVI. In multivariate analyses,
higher BMI was independently associated with younger age
at diagnosis (odd ratio (OR)=0.97, 95% confidence interval
(CI)=0.96-9.97) and the presence of lower tumor FIGO grade
(OR=0.98, 95% CI=0.97-0.99). Conclusion: Increased BMI
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was significantly associated with lower tumor grade and
younger patient age at diagnosis. Increased body mass index
was not associated with LVI. The higher prevalence of obesity
in young women with EC is alarming.
There is growing evidence that obesity is a significant risk
factor for type I endometrial carcinoma (EC)(1, 2). As an
obesity epidemic has been raging in the United States and
Europe over the last few decades (3-5), it is critical to fullyunderstand not only the correlation between obesity and the
development of EC, but also the impact of obesity on tumor
factors and survival endpoints in women with EC.
In a large study, the relative risk (RR) of death for
morbidly obese women with uterine cancer and a body mass
index (BMI) of >40 was 6.25 kg/m2. Among patients with
different cancer types, the RR of death was the highest for
patients with uterine cancer compared to RR of only 2.12 in
patients with breast carcinoma (6).
The impact of obesity on the outcome of women with EC
is controversial. While some investigators reported a
significant association between lower tumor grade and
increased BMI, all-cause mortality is significantly increased
in obese women with EC (7-8).
Some of the factors linking obesity to cancer development
and progression appear to be excessive exposure to various
growth factors produced by excessive adipose tissue or
adipokines in obese women. The negative impact of some of
these adipokines was strongly linked to obesity in patients with
different sites of cancer e.g. of the breast (9), and colon (10,
11). Few studies suggest that some of these adipokines are also
involved in angiogenesis and progression of EC (12-14).
In a study of 1,312 women with breast carcinoma, the
presence of lymphovascular invasion (LVI) was
independently correlated with increase in BMI (15).
There is a paucity of data examining obesity, as measured
by BMI and its association with LVI in women with EC. The
purpose of the present study was to primarily investigate the
relationship between obesity and LVI among women with
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uterine endomerioid carcinoma. Additionally, we investigated
the association between BMI and other traditional prognostic
factors in this large cohort of patients.

Patients and Methods
This is an Institutional Review Board (IRB)-approved study. We
retrospectively reviewed our database of 1,910 patients with EC and
we identified 1,341 women with 2009 International Federation of
Gynecology and Obstetrics (FIGO) stage I-IVB EC who underwent
hysterectomy at our institution between January 1985 and May
2014. BMI at the time of hysterectomy was documented for all
patients included in the study.
Patients were then categorized into four groups based on their
BMI at the time of hysterectomy according to World Health
Organization (WHO) classification (16); normal (BMI <24.9 kg/m2),
overweight (BMI 25.0-29.9 kg/m2), obese (BMI 30.0-34.9 kg/m2)
and morbidly obese (BMI >35.0 kg/m2). The four groups were then
compared with regards to patient demographics, tumor
characteristics, treatment received and survival end-points. The
presence of LVI was confirmed by a gynecologic pathologist (ZZ).
All patients underwent hysterectomy, salpingo-oophorectomy,
pelvic and para-aortic lymph node evaluation with or without
lymphadenectomy and peritoneal cytology.
Since obesity is more prevalent in women with type I EC, only
patients with endometrioid histology were included in the study.
Patients with synchronous invasive malignancies were excluded
from this study as their inclusion may impact the prevalence of LVI
in the study population. Patients who received preoperative radiation
treatment or neoadjuvant chemotherapy were also excluded.
The Kruskal-Wallis test was used to test for differences for
numerical variables. Chi-Squared test of independence was used
to test for association. Cox regression analysis was used to explore
relationships between BMI and other factors. All univariate
variables were entered into the model. Stepwise selection was then
used to remove non-significant predictors one at a time. Variables
that remained in the model were significant at p<0.05. Odd ratios
(OR) and 95% confidence intervals (CI) are calculated. Statistical
analysis was performed using SAS 9.4 (Cary, NC, USA).

Table I. Characteristics of the 1,341 women in our study cohort.
Variable
Median (range) age, years

62.0 (26-96)

Race (n%)
White
African American
Others

995 (74.2%)
300 (22.4%)
46 (3.4%)

Median (range) BMI kg/m2
BMI category, n(%)
Normal
Overweight
Obese
Morbidly obese
Median (range) BMI (kg/m2) by age group
50 years or younger (222 patients)
51-60 (403 patients)
61-70 (396 patients)
71 years or older (320 patients)

34.3 (15.7-71.3)

175
259
279
628

(13.1%)
(19.3%)
(20.8%)
(46.8%)

36 (19.31-71.3)
36 (19.7-62.8)
34.5 (15.7-65.44)
30.9 (17.9-57.61)

Tumor grade, n (%)
1
2
3

863 (64.4%)
284 (21.2%)
194 (14.5%)

Positive lymphovascular invasion, n (%)

224 (16.7%)

Lower uterine segment involvement, n (%)

340 (25.4%)

Peritoneal cytology, n (%)
Negative
Positive
Not examined

340 (25.4%)
64 (4.8%)
148 (11.0%)

Median no. (range) of LN examined
Median no. (range) of positive LN

6.0 (0-68)
0 (0-16)

Results
Median no (range) of dissected pelvic LN lymph nodes 5.0 (0-45)

Our study cohort included 1,341 patients. The median BMI of the
study cohort was 34.3 (range=15.7-71.3 kg/m2). Morbidly obese
women constituted 46.8% of the study cohort. LVI was present in
224 patients (16.7%) while FIGO grade 1 disease was present in
863 patients (64.4%). Table I shows patients, demographics,
tumor and treatment characteristics of the study cohort.
Bivariate analysis was conducted with the following
covariates: age (continuous variable), race (African American
vs. non-African American), BMI (continuous variable and
categorical), FIGO grade, FIGO stage, lower uterine segment
(LUS) involvement, LVI, status of peritoneal cytology,
adnexal involvement, number of total lymph node examined
(continuous variable) and the use of adjuvant therapies.
In bivariate analyses, as shown in Table II, BMI was not
significantly associated with LVI, LUS involvement, FIGO
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Median no. (range) of dissected paraaortic LN
Adnexal involvement
2009 FIGO staging
IA
IB
II
IIIA
IIIB
IIIC1
IIIC2
IVA
IVB

0 (0-32)
60 (4.5%)

922 (68.8%)
208 (15.5%)
80 (6.0%)
32 (2.4%)
7 (0.5%)
35 (2.6%)
29 (2.2%)
3 (0.2%)
25 (1.9%)

BMI: Body mass index; FIGO: International Federation of Gynecology
and Obstetrics; LN: lymph nodes.
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Table II. Patient characteristics of the 1,341 women in our study cohort,
according to the four BMI Categories.
Variable

Median (range)
age in years

Normal Overweight
(N=175)
(13%)

(N=259)
(19.3%)

Obese Morbidly p-Value
obese
(N=279) (N=628)
(20.8%) (46.8%)

64
(30-76)

61
(29-92)

61
(30-96)

60
(26-95)

Race
White
African
American
Other

0.0323
137
(78.3%)
36
(20.6%)
2 (1.1%)

196
(75.7%)
47
(18.2%)
16
(6.2%)

206
454
(73.8%) (72.5%)
67
150
(24.0%) (24.0%)
6
22
(2.2%) (3.5%)

Grade
1
2
3

Positive
lymphovascular
invasion

Positive
Not done

LUS involvement

Discussion

0.0003
112
(64.0%)
36
(20.6%)
27
(15.4%)

150
(57.9%)
64
(24.7%)
45
(17.4%)

159
442
(57.0%) (70.4%)
64
120
(22.9%) (19.1%)
56
66
(20.1%) (10.5%)

28
(16.0%)

44
(17.0%)

56
96
(20.1%) (15.3%)

Cytology
Negative

<0.0001

0.3535

0.6501
144
(82.3%)
9
(5.1%)
22
(12.6%)

222
(85.7%)
14
(5.4%)
23
(8.9%)

229
534
(82.1%) (85.0%)
12
29
(4.3%) (4.6%)
38
65
(13.6%) (10.4%)

40
(22.9%)

76
(29.3%)

71
153
(25.5%) (24.4%)

0.3792

Median no. (range) 5
of LNs examined (0-45)

8
(0-40)

6
(0-68)

7
(0-68)

0.0038

Median no. (range) 0
of positive LNs
(0-8)

0
(0-9)

0
(0-9)

1
(0-16)

0.3615

Median no. (range) 4
of pelvic LN
(0-45)

5
(0-39)

5
(0-42)

7
(0-65)

0.0148

FIGO staging
I
II
III
IV

0.3353
152
(86.9%)
8
(4.6%)
13
(7.4%)
2
(1.1%)

206
(79.5%)
20
(7.7%)
28
(10.8%)
5
(1.9%)

stage, or positive peritoneal cytology. There was a statistically
significant association between increased BMI category and
low FIGO grade 1, and African American race. There was also
a statistically significant association between increased BMI
and younger patient’s age at diagnosis. Additionally, there was
a statistically significant association between increased BMI
and a higher number of dissected lymph nodes.
In multivariate analyses, the two factors that were
significantly associated with higher BMI were lower
FIGO tumor grade (OR=0.98, 95% CI=0.97-0.99,
p<0.001) and younger age at diagnosis (OR=0.97, 95%
CI=0.96-9.97, p<0.001).

234
538
(83.9%) (85.7%)
14
38
(5.0%) (6.1%)
24
38
(8.6%) (6.1%)
7
14
(2.5%) (2.2%)

BMI: Body mass index; LUS: lower uterine segment, LN: lymph nodes,
FIGO: International Federation of Gynecology and Obstetrics.

Obesity is associated with significant increase in both
morbidity and all-cause mortality of women with EC (17,
18). Obese women are more likely to have comorbid diseases
including hypertension, diabetes mellitus, hyperlipidemia and
coronary artery disease. Medical comorbidities including
obesity in women with EC are the main cause of death in
this population (19, 20).
To our knowledge, there exist few studies to date to have
discussed the impact of obesity on clinicopathological
variables in patients with endometrioid type of EC. However,
none of the studies examined the association between obesity
and LVI despite the fact that LVI is an important prognostic
factor in women with EC (7, 17, 21-23).
In contrast to breast carcinoma, where there was a
significant correlation between BMI and the presence of
LVI (15), our study showed that there is no significant
association between BMI and LVI. In agreement with other
investigators, our study showed that there is a strong
association between grade 1 tumor and increased BMI (7,
24, 25). However, obese patients with endometrioid
carcinoma paradoxically seemed to have higher all-cause
mortality rates.
The favorable impact of lower FIGO grade in obese women
may be masked or diluted since most of these patients succumb
to morbid conditions associated with their obesity (20, 24).
Similar to our study findings, Pavelka et al. published a
review of 356 consecutive patients with EC and reported that
women with BMI ≥40 kg/m2 were more likely to be
diagnosed with grade 1 tumor than patients with a BMI less
than 30 kg/m2 (17). In a study by the Gynecologic Oncology
Group, of 2596 women with EC, obese women were likely
to have fewer nodal metastases due to hormone receptor
positivity and low-grade lesions (7).
The median age of our morbidly obese women was 59 years
which is significantly lower than that of women of normal
weight included in the study. The association between younger
age and higher BMI has also been reported by other
investigators (26, 27). In patients with early-stage endometrioid
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carcinoma, and regardless of the tumor risk factors, the main
cause of death after treatment is comorbid conditions including
obesity (20). The high percentage of morbidly obese women
(BMI >40 kg/m2) of 46.8% in our study cohort is an alarming
sign and may have significant clinical impact. The percentage
of morbidly obese women with EC reported in other studies
ranged from 10-22% (7, 17). The increased percentage of
morbidly obese women in our study could only be explained
by the fact that Michigan has had one of the highest rates of
obesity in the USA for over a decade (28).
Considering that 35.5 % of women in USA are obese (4)
with projections of 65 million more obese adults in the USA
and 11 million more obese adults in the UK by 2030 (5), it is
essential to counsel women with EC about the significant
risks of obesity. A weight-loss program could be essential in
reducing the negative impact of obesity on overall survival in
women with EC. While weight loss is a challenging process,
it is achievable in overweight and obese EC survivors (29).
The main limitation to the current study is its retrospective
nature with its inherent bias. We did not study survival endpoints with BMI since the study included all FIGO stages
that required different postoperative management including
different adjuvant therapies.
However, our study included a large cohort of patients
solely with endometrioid histology in contrast to other studies
that included all histological sub-types (7). Additionally, the
presence of LVI was confirmed by a gynecologic pathologist.

Conclusion
In the present large study, increased BMI was associated with
lower tumor grade and young patients’ age at presentation.
Increased body mass index was not statistically associated
with LVI. Considering the alarming increase in the percentage
of women with morbid obesity in our study and globally,
counseling women for weight loss should be routine practice
for physicians taking care of women with EC.
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